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Summary The aim of this study was to evaluate the new monoclonal tumour marker CA 242 in the diagnosis
of pancreatic carcinoma and to compare it with the established markers CA 50 and CEA. Serum concentra-
tions were determined in 113 patients with jaundice, in 20 patients with laboratory values suggesting
cholestasis, and in 60 patients with a suspicion to have chronic pancreatitis. Twenty-four of these 193 patients
had pancreatic carcinoma and two patients had carcinoma of papilla of Vater. The sensitivities of CA 242, CA
50 and CEA were 80.7%, 96.1%, and 92.3%, respectively. The specificities were 79.0%, 58.0%, and 59.2%.
The sensitivities of combinations of CA 50 and CEA with CA 242 did not exceed the sensitivity of CA 50
alone. The specificity of CA 242 was improved by combining it with CEA (92.2%). The serum marker CA 242
seems to be less sensitive than CEA and CA 50 in the detection of pancreatic carcinoma, but it may prove
useful because of its high specificity.
Pancreatic carcinoma is still a problematic cancer despite the
improving imaging methods. We still lack a good method to
screen symptomless people and to diagnose cancer early
enough for curative treatment. Only about 10% of patients
with pancreatic carcinoma are diagnosed early enough for
resection, and the 5-year prognosis of these patients with
resectable tumour is only 4% or less (Longmire, 1984;
Eskelinen et al., 1991). Therefore, every effort should be
made to develop better methods for early diagnosis. At the
present time tumour markers seem to be most ideal for this
purpose. A variety of tumour markers have been demon-
strated to be associated with pancreatic carcinoma, but the
sensitivities and specificities of these tumour markers have
not yet reached the level for screening an asymptomatic
population. The most intensively studied tumour markers in
pancreatic cancer are carcinoembryonic antigen (CEA)
(Kalser et al., 1978; Hansen et al., 1974; Begent, 1984), CA
50 (Lindholm et al., 1983; Holmgren et al., 1984; Paganuzzi
et al., 1985; Jalanko et al., 1985; Habib et al., 1986a), and
CA 19-9 (Haglund et al., 1986; Kuusela et al., 1991). CA 242
is a novel tumour associated antigen, which has been sug-
gested as a potential candidate for a serum tumour marker in
pancreatic cancer (Haglund et al., 1989; Kuusela et al., 1991).
The aim of this study was to evaluate the diagnostic accuracy
of CA 242 in the detection of pancreatic cancer and to
compare it with the established serum markers CEA and CA
50. The serum levels from patients with pancreatic cancer
were compared with those from patients with benign pan-
creatic diseases, and with benign and malignant biliary tract
and hepatocellular diseases.
Patients
The study population consisted of all consecutive jaundiced
and/or cholestatic patients admitted to or attending Kuopio
University Hospital during the two-and-a-half year period
from the beginning of December 1985 to the end of May
1988. The limits for inclusion to the study were defined as
follows: a serum bilirubin level exceeding 40 micromoles per
liter (normal value in our laboratory < 17tsmol 1-', and/or
serum alkaline phophatase level above 350 IU I (normal
value in our laboratory < 210U/I-1) in relation to serum
gamma glutamyltranspeptidase level above 100 IU 1' (nor-
mal value in our laboratory < 32 U 1`), or liver-specific
alkaline phosphatase elevated. In addition to these jaundiced
or cholestatic patients the following patients were included:
patients with the history of two or more acute pancreatitis,
patients who had continuous or recurring abdominal pain
with raised serum or urine amylase levels measured at least
three times, patients who had been suspected to have a
pancreatic tumour or chronic pancreatitis in ultrasound or
computed tomography examination. Excluded were patients
with the following criteria: age less than 15 years, pregnancy,
jaundice developing in the intensive care unit, a history of
recent heart surgery, insufficient cooperation, acute alcoholic
pancreatitis, disseminated malignancy, parenchymal liver
disease diagnosed within 2 days of admission, need for
emergency surgery. One hundred and ninety-three patients
were included altogether. One hundred and thirteen of these
patients were jaundiced and 20 had laboratory values sugges-
ting unjaundiced cholestasis. Sixty patients were studied
according to the criteria of suspicion of chronic pancreatitis.
The distribution of the final diagnosies is seen in Table I.
Benign diseases constituted the clear majority (81.6%) of
patients, choledochal stone disease being the biggest group.
There were altogether 24 patients with a final diagnosis of
carcinoma of the head of the pancreas, and two patients with
a diagnosis of carcinoma of the papilla of Vater.
Methods
A clinical assessment with routine laboratory tests was made
for all patients on admission to hospital. Complementary and
more detailed laboratory tests were made on all patients the
day after admission to the hospital including a wide variety
of hepatobiliary laboratory tests and serologic tests. If the
clinical assessment raised a suspicion of extrahepatic obstruc-
tion, ultrasound, computed tomography and endoscopic ret-
rograde cholangiopancreatography were performed in this
sequence as soon as possible. If within 2 days after entering
the study, the patient's disease seemed most likely to be of
hepatocellular origin, no imaging studies were made, but liver
biopsy was obtained instead. Secretine-ceruleine test was per-
formed if chronic pancreatitis was suspected.
All the patients involved in the study were scheduled for
re-examination 6 months after entering the study, and the
clinical data of the hospital records were reviewed retrospec-
tively after a follow-up period of 2 years. A final diagnosis of
a pancreatic cancer or cancer of the papilla of Vater was
based on histology in 16 cases, on cytology in three cases, on
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Table I Distribution of the I
Final diagnosis
Extrahepatic diseases
I. Benign diseases
Choledochal stone
Acute cholecystitis
Chronic cholecystitis
Bile duct stricture
Spasm of sphincter Oddi
Postoperative bile duct compression
by an abcess
Bil duct adenoma
Fibroma ofjejunal mesentery
Acute nonalcoholic pancreatitis
Acute alcoholic pancreatitis
Chronic nonalcoholic pancreatitis
Chronic alcoholic pancreatitis
Functional gastrointestinal disorder
II. Malignant diseases
Pancreatic carcinoma
Carcinoma of the papilla ofVater
Cholangiocarcinoma of the extra-
hepatic bile ducts
Carcinoma of gallbladder
Hodgkin's lymphoma
Retroperitoneal sarcoma
Intrahepatic diseases
I. Acute parenchymal diseases
Hepatitis A
Hepatitis non-A-non-B
Cytomegalovirus hepatitis
Toxic hepatitis
Benign postoperative jaundice
Sepsis
II. Congestive heart fisease
Chronic parenchymal diseases
Alchoholic cirrhosis of the liver
Cirrhosis of the liver of
unknown etiologya
Chronic active hepatitis
Gilbert's syndrome
Intrahepatic cholangiocarcinoma
Hepatocellular carcinoma
Total
a Liver biopsy done.
final diagnoses
No. ofpatients %
160 82.9
122
50
6
2
3
4
2
4
2
22
12
13
38
24
2
7
3
1
33
15
l 4
2
3
2
2
18
7
3
2
2
2
193
Sensitivity = TP/(TP + FN), Specificity = TN/(TN + FP),
Positive predictive value = TP/(TP + FP),
Negative predictive value = TN/(TN + FN).
(TP = true positive, TN = true negative, FP = false positive,
FN = false negative).
Results
CA 242 inpancreatic cancer
In patients with pancreatic cancer (n = 26), the median serum
CA 242 value was 113.8 U ml-' (range 5.0 U ml-'
27100 U ml-). When we used the cut-off level of 20 U ml-',
21 of the 26 patients (80.7%) with pancreatic cancer had a
serum CA 242 concentration above this level (Figure 1, Table
II). There were 35 false positives: 13 cases of choledochal
stones, five cases of chronic pancreatitis, four cases of bile
duct cancer, two cases of alcoholic liver cirrhosis, and one
with nonalcoholic cirrhosis, one case of spasm of the sphinc-
ter of Oddi, two cases of acute pancreatitis, and one of acute
cholecystitis, one case of a benign bile duct stricture, one case
of congestive heart disease, one case of cytomegalo virus
hepatitis, one case of drug-induced hepatitis and two patients
with a functional gastrointestinal disorder. The specificity of
17.1 CA 242 was thus 79.0%.
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operative or endoscopic macroscopic morphologic findings in
three cases, and on the imaging methods in four cases. The
diagnosis of chronic pancreatitis was based on histology in
seven cases, on cytology in one case, on secretine-ceruleine
test in six cases, on the imaging methods in 14 cases and on
clinical course of the disease in six cases.
Assays
Serum samples were drawn on the patient's admission to
hospital before surgery or biopsy and all serum samples were
stored frozen (- 20°C) until analysed. The cut-off values of
2.5 ng ml-', 17 U ml-' and 20 U ml-' (Nilsson et al., 1988)
were used for CEA, CA 50 and CA 242, respectively.
Serum CA 242 concentrations were determined by using a
dissociation- enhanced lanthidine fluoroimmonoassay pro-
totype kit (DELFIA; Pharmacia Diagnostics, Uppsala,
Sweden) (Nilsson et al., 1988). The assay was done according
to the protocol recommended by the manufacturer. Serum
CA 50 concentrations were determined by using monoclonal
antibody (C-50) in delayed immunofluorescence technique
(TR-FIA, Wallac, Turku, Finland). Serum CEA concentra-
tions were determined by using monoclonal antibody in
delayed immunofluorescence technique (TR-FIA, Wallac,
Turku, Finland).
The differences between groups were analysed by the Wil-
coxon nonparametric test. Diagnostic sensitivity, specificity,
positive predictive value ( = PV + ) and negative predictive
value ( = PV-) were calculated according to the following
formulas:
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Figure 1 Serum CA 242 concentrations in patients with panc-
reatic cancer (PC), chronic pancreatitis (CP), acute pancreatitis
(AP), choledochal stone disease (CS), benign liver disease (BLD),
malignant liver disease (MLD) and bile duct cancer (BDC). The
cut-off value of 20 U ml-' for the CA 242 assay is marked as a
dashed line
Table II Serum concentrations (U ml t, median, interquartile range)
ofCA 242 benign and malignant diseases ofthepancreas, liverand bile
ducts
Disease n Median Interquartile range
Pancreatic cancer 26 113.8 22.3-229.1
Chronic pancreatitis 34 9.2 5.2-12.3
Acute pancreatitis 6 11.2 9.7-26.7
Choledocholithiasis 50 10.8 5.0-20.4
Benign liver disease 29 8.5 5.0-16.0
Malignant liver disease 4 8.6 5.0-14.7
Bile duct carcinoma 10 11.9 5.0-23.0
n = number ofcases.
eniCA 242 IN PANCREATIC CANCER 733
Table III Sensitivity, specificity, PV + and PV - ofCA 242, CA 50
and CEA in detecting pancreatic cancer (n = 26) among patients with
benign diseases of the pancreas, liver and bile ducts (n = 151)
Diagnostic
parameter CA 242 CA 50 CEA
Sensitivity 80.7% 96.1% 92.3%
Specificity 79.0% 58.0% 59.2%
Predictive
value
-positive 37.5% 26.3% 26.0%
-negative 96.3% 98.9% 98.0%
Cut-off values: CA 242: 20Uml-'; CA 50: 17Uml-'; CEA:
2.5 ngml-'
CA 242 in hepatobiliary malignancies
The median serum CA 242 concentration in the patients with
carcinoma of the biliary tract (seven cholangiocarcinomas,
three carcinomas of the gallbladder) was 11.9 U ml-' (Table
II). When we used the cut-off level of 20 U ml-' for CA 242,
four patients with a carcinoma of the biliary tract was above
this level. In malignant liver diseases (n = 4), the median
serum CA 242 concentration was 8.6 U ml-', and none of
them were above the cut-off level of 20 U ml-I (Figure 1,
Table II).
In the patients with a malignant hepatopancreatico-biliary
disease (n = 42), the mean serum CA 242 concentration
(887.4 U ml-' was significantly higher (P<0.0001, Wilcox-
on's test) than the mean value (59.2 U ml-') of the patients
with benign disease (n = 151).
CA 242 in benign hepatopancreatico-biliary diseases
Among the benign diseases, the highest values were measured
in choledochal stone disease (median 10.8 U ml-', range
5.0-1893.0 U ml-'), and in 26% (13/50) of patients the
serum CA 242 value was above the cut-off value of
20 U ml-' (Figure 1, Table II). In the patients with a benign
liver disease, 20.6% (6/29) of patients had a higher value
than 20 U ml-'. In the patients with acute or chronic panc-
reatitis the respecting values were 33% (2/6) and 14% (5/34)
(Figure 1, Table II).
Comparison and combinations ofthe markers
The diagnostic sensitivities of CA 242, CEA and CA 50 were
80.7%, 92.3% and 96.1%, and specificities 79.0%, 59.2%
and 58.0%, respectively. The sensitivity, specificity, PV+
and PV- of the combinations of the markers are presented
in Table IV.
Discussion
The clinical role of tumour markers in pancreatic cancer is
not clearly established. No ideal tumour marker has been yet
developed. The lack of specificity is one of the great prob-
lems. For example, elevated CA 50 and CEA values are also
seen in hepatocellular jaundice, and in benign hepatic and
extrahepatic diseases (Jalanko et al., 1985; Bruhn et al., 1985;
Habib et al., 1986b, c; Chan et al., 1985; Hansen et al., 1974;
Kalser et al., 1978; Carr-Locke, 1980).
In the present study, the clinical value of a new serum
tumour marker CA 242 was evaluated. Monoclonal antibody
C 242 was obtained after immunisation of mice with a
human colorectal adenocarcinoma cell line (Lindholm et al.,
1985). The exact nature of the antigen determinant is not
known, but it seems to be a sialylated carbohydrate structure
and chemically closely related to CA 19-9 and CA 50 (Hag-
lund et al., 1989). In our study, the sensitivity of CA 242 was
considerably high (80.7%), even though lower than that of
CEA or CA 50. On the other hand, the specificity of CA 242
(79.0%) was highest of the three markers. In a study of
Haglund et al. (Haglund et al., 1989) a slightly lower (65%)
sensitivity was reached than in the present series, but the
specificity was not determined. In our study, as well as in the
study of Haglund et al. (Haglund et al., 1989) the upper limit
of normal 20 U ml' was used for the assay as based on
serum levels of healthy blood donors (Nilsson et al., 1988). It
has been recommended that the cut-off level should be deter-
mined by using the 95th percentile of benign diseases,
because it tests best the real clinical value of a tumour
marker (Roberts, 1986). In the present series, by using this
criteria, the cut-off value level would have been 63 U ml-.
The sensitivity of CA 242 would have been 61.5% and
specificity 95.2%. The present patient population is a con-
secutive series of patients admitted to one university hospital,
and a large proportion of these patients had whether jaun-
dice (113/193) or unjaundiced cholestasis (20/193). From this
point of view, our patient material can be well regarded as
clinically relevant, and therefore the high specificity of CA
242 must be emphasised.
It has been noticed in many previous studies, that the
combinations of these markers give only little further benefit.
This was the case also in the present study, since the
specificity of CA 242 alone was good, and the sensitivity CA
50 alone was equal to those of the combinations. It is clear
that if we require for example, two tests to be positive, we
can reach high specificity, but at the cost of sensitivity, and if
we require only either of the tests to be positive, we can
reach higher sensitivity with rather low specificity. In the
light of the present study, the most ideal combination would
seem to be a combination of CA 242 and CEA. If we have
either of the tests positive, we reach high sensitivity (96.1%)
and if both tests are positive, we can reach high (92.2%), too
(Table IV).
It can be concluded, that the sensitivity of CA 242 is lower
than that of the older markers CA 50 and CEA in the
diagnosis of pancreatic cancer, but it may prove useful
because of its higher specificity. The relative insensitivity of
CA 242 can be improved by combining it with CEA or CA
50.
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Table IV Sensitivity, specificity, PV + and PV- ofCEA, CA 50 and CA 242 used as a testpanel
in detecting pancreatic cancer (n = 26) among patients with benign diseases ofthe pancreas, liver
and bile ducts (n = 151)
CEA,
CEA CEA CA 50 CA 242 CA 242 CA 50
Assay and and and or or and
parameters CA 50 + CA 242 + CA 242 + CA 50 + CEA + CA 242 +
Sensitivity 88.0% 76.9% 80.7% 96.1% 96.1% 76.9%
Specificity 72.4% 92.2% 80.2% 40.7% 47.3% 89.2%
Predictive
value
-positive 33.3% 60.6% 38.8% 20.1% 22.1% 52.6%
-negative 97.5% 96.2% 96.4% 98.5% 98.7% 96.1%
Cut-off values: CA 242: 20 U ml '; CA 50: 17 U ml-'; CEA: 2.5 ng ml '734 P.A. PASANEN et al.
References
BEGENT, R.H.J. (1984). The value of carcinoembryonic antigen
measurement in clinical practice. Ann. Clin. Biochem., 21, 231.
BRUHN, H.D., EVERDING, A., JOOS, B. & HEDDERICH, J.
(1985). Clinical experience with the carbohydrate antigen CA-50
in the serum of carcinoma patients. In Tumour Marker Antigen,
Holmgren, J. (ed.), p. 94. Studentlitteratur: Lund, Sweden.
CARR-LOCKE, D.L. (1980). Serum and pancreatic juice carcino-
embryonic antigen in pancreatic and biliary disease. Gut, 21, 656.
CHAN, S.H., LINDHOLM, L., WONG, L. & OON, C.J. (1985). Tumour
markers in hepatocellular carcinoma in Singaporean Chinese. In
Tumour Marker Antigen, Holmgren, J. (ed.), p. 106. Studenlit-
teratur: Lund, Sweden.
ESKELINEN, M., LIPPONEN, P., MARIN, S. & 6 others (1991). Prog-
nostic factors in human pancreatic cancer, with special reference
to quantitative histology. Scand. J. Gastroenterol., 26, 483.
HABIB, N.A., HERSHMAN, M.J., HABERLAND, F., PAPP, L., WOOD,
C.B. & WILLIAMSON, R.C.N. (1986a). The use of CA-50 radioim-
munoassay in differentiating benign and malignant pancreatic
disease. Br. J. Cancer, 53, 697.
HABIB, N.A., HERSHMAN, M.J., PAPP, L., SWIFT, I., WILLIAMSON,
R.C.N. & WOOD, C.B. (1986b). The detection of colorectal car-
cinomas with the use of CA-50 radioimmunoassay inhibition test.
Int. J. Colorect. Dis., 1, 186.
HABIB, N.A., HERSHAM, M.J., SMADJA, C. & WOOD, C.B. (1986c).
The use of CA-50 radioimmunoassay inhibition test in the differ-
ential diagnosis of benign and malignant liver diseases. Br. J.
Surg., 73, 758.
HAGLUND, C., ROBERTS, P., KUUSELA, P., SCHEININ, T.M.,
MAKELA, 0. & JALANKO, H. (1986). Evaluation of CA 19-9 as a
serum tumour marker in pancreatic cancer. Br. J. Cancer, 53,
197.
HAGLUND, C., LINDGREN, J., ROBERTS, P., KUUSELA, P. & NORD-
LING, S. (1989). Tissue expression of the tumour associated
antigen CA 242 in benign and malignant pancreatic lesions. A
comparison with CA 50 and CA 19-9. Br. J. Cancer, 60, 845.
HANSEN, H.J., SNYDER, J.J., MILLER, E. & 4 others (1974). Car-
cinoembryonic antigen (CEA) assay. A Laboratory adjunct in the
diagnosis and management of cancer. Human Pathol., 5, 139.
HOLMGREN, J., LINDHOLM, L., PERSSON, B. & 8 others (1984).
Detection by monoclonal antibody of carbohydrate antigen CA
50 in serum of patients with carcinoma. Br. Med. J., 288, 1479.
JALANKO, H., HAGLUND, C., ROBERTS, P. & KUUSELA, P. (1985).
Tumor markers in gastrointestinal cancers. In Tumour Marker
Antigen, Holmgren, J. (ed.), p. 114. Studentlitteratur: Lund,
Sweden.
KALSER, M.H., BARKIN, J.S., REDLHAMMER, D. & HEAL, A. (1978).
Circulating carcinoembryonic antigen in pancreatic carcinoma.
Cancer, 42, 1468.
KUUSELA, P., HAGLUND, C. & ROBERTS, P.J. (1991). Comparison of
a new tumour marker CA 242 with CA 19-9, CA 50 and car-
cinoembryonic antigen (CEA) in digestive tract diseases. Br. J.
Cancer, 63, 636.
LINDHOLM, L., HOLMGREN, J., SVENNERHOLM, L. & 5 others
(1983). Monoclonal antibodies against gastrointestinal tumour-
associated antigens isolated as monosialogangliosides. Int. Arch.
Allergy Appl. Immunol., 71, 178.
LINDHOLM, L., JOHANSSON, C., JANSSON, E.-L., HALLBERG, C. &
NILSSON, 0. (1985). An immunoradiometric assay (IRMA) for
the CA-50 antigen. In Tumour Marker Antigen, Holmgren, J.
(ed.), p. 123. Studentlitteratur: Lund, Sweden.
LONGMIRE, W.P., Jr (1984). Cancer of the pancreas: Palliative oper-
ation, Whipple procedure, or total pancreatectomy. World J.
Surg., 8, 872.
NILSSON, O., JANSSON, E.-L., JOHANSSON, C. & LINDHOLM, L.
(1988). CA-242, a novel tumour associated carbohydrate antigen
with increased tumour specificity and sensitivity. J. Tumor
Marker Oncol., 3, 314.
PAGANUZZI, M., MARRONI, P., BOCCARDO, F. & 4 others (1985).
Clinical evaluation of CA-50 in sera of patients with different
tumours. In Tumour Marker Antigen, Holmgren, J., (ed.), p. 134.
Studentlitteratur: Lund, Sweden.
ROBERTS, P.J. (1986). The clinical value of tumour markers. Ann.
Chir. Gynaecol., 75, 247.